Peripheral fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with growth hormone deficiency

Clinical Endocrinology

Volumn 64, Issue 6, 2006, Pages 632-639

  Gómez, José Manuel ^a,b   Sahún, Manel ^a   Vila, Ramon ^a   Domènech, Pere ^a   Catalina, Pablo ^b   Soler, Juan ^a   Badimón, Lina ^b  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; CELL ADHESION MOLECULE; CYTOKINE; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOLYTIC FACTOR; GLUCOSE; GROWTH HORMONE; HORMONE; INSULIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PADGEM PROTEIN; SOMATOMEDIN C; THROMBIN ANTITHROMBIN COMPLEX; TRANSACTIVATOR PROTEIN; TRIACYLGLYCEROL; VASCULAR CELL ADHESION MOLECULE 1;

ADRENAL INSUFFICIENCY; ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD VESSEL REACTIVITY; BODY COMPOSITION; BODY FAT; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES INSIPIDUS; DOPPLER FLOWMETRY; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; GROWTH HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOPITUITARISM; HYPOTHYROIDISM; INTIMA; MALE; NEPHELOMETRY; PATIENT SELECTION; PRIORITY JOURNAL; RADIOIMMUNOASSAY; THICKNESS; TUNICA MEDIA; WAIST HIP RATIO;

ADULT; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BODY COMPOSITION; BODY MASS INDEX; BRACHIAL ARTERY; CASE-CONTROL STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; FIBRINOLYSIS; GROWTH HORMONE; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOPITUITARISM; MALE; MIDDLE AGED; REGIONAL BLOOD FLOW; TIME FACTORS;

EID: 33646865444     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2006.02518.x     Document Type: Article

References (49)

1. Rosén, T. Bengtsson, B.-Å. 1990 Premature mortality due to cardiovascular disease in hypopituitarism. Lancet, 336, 285 288.
2. Bates, A.S., Van't Hoff, W., Jones, P.J. Clayton, R.N. 1996 The effect of hypopituitarism on life expectancy. Journal of Clinical Endocrinology and Metabolism, 81, 1169 1172.
3. Tomlinson, J.W., Holden, N., Hills, R.K., Wheatley, K., Clayton, R.N., Bates, A.S., Sheppard, M.C. Stewart, P.M. 2001 Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. Lancet, 357, 425 431.
4. Bülow, B., Hagmar, L., Mikoczy, Z., Nordstrom, C.H. Erfurth, E.M. 1997 Increased cerebrovascular mortality in patients with hypopituitarism. Clinical Endocrinology, 46, 75 81.
5. Abstract, R., Bengtsson, B.-Å., Hernberg-Stahl, E., Monson, J.P., Tauber, J.P., Wilton, P. Wuster, C. 1999 GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clinical Endocrinology, 50, 703 713.
6. Wuster, C., Slenczka, E. Ziegler, R. 1991 Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary insufficiency: need for additional growth hormone substitution? Klinische Wochenschrift, 69, 769 773.
7. De Boer, H., Block, G.J. Van der Veen, E.A. 1995 Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews, 16, 63 86.
8. Klibanski, A. 2003 Growth hormone and cardiovascular risk markers. Growth Hormone and IGF Research, 13, S109 S115.
9. Beshyah, S.A., Shahi, M., Skinner, E., Sharp, P., Foale, R. Johnston, D.G. 1994 Cardiovascular effects of growth hormone replacement therapy in hypopituitary adults. European Journal of Endocrinology, 130, 451 458.
10. Caidahl, K., Edén, S. Bengtsson, B.-Å. 1994 Cardiovascular and renal effects of growth hormone. Clinical Endocrinology, 40, 393 400.
11. Weaver, J.U., Monson, J.P., Noonan, K., John, W.G., Edwards, A., Evans, K.A. Cunningham, J. 1995 The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. Journal of Clinical Endocrinology and Metabolism, 80, 153 159.
12. Johansson, G., Rosén, T., Lindstedt, G., Bosæus, I. Bengtsson, B.-Å. 1996 Effect of 2 years of GH treatment on body composition and cardiovascular risk factors in adults with GH deficiency. Endocrinology and Metabolism, 4, 3 12.
13. Pfeifer, M., Verhovec, R., Zizec, B., Prezelj, J., Poredos, P. Clayton, R.N. 1999 Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults. Journal of Clinical Endocrinology and Metabolism, 84, 453 457.
14. Silha, J.V., Kresk, M., Hana, V., Marek, J., Weiss, V., Jezkova, J., Rosika, M., Jarkovska, Z. Murphy, L.J. 2005 The effects of growth hormone status on circulating levels of vascular growth factors. Clinical Endocrinology, 63, 79 86.
15. McCallum, R.V., Sainsbury, C.A.R., Spier, A., Dominiczak, A.F., Petrie, J.R., Sattar, N. Connell, J.M.C. 2005 Growth hormone replacement reduces C-reactive protein and large-artery stiffness but does nor alter endothelial function in patients with adult growth hormone deficiency. Clinical Endocrinology, 63, 473 479.
16. Leonsson, M., Hulthe, J., Johannsson, G., Wiklund, O., Wilstrand, J., Bengtsson, B.A. Oscarsson, J. 2003 Increased interleukin-6 levels in pituitary-deficient patients are independently related to their carotid intima-media thickness. Clinical Endocrinology, 59, 242 250.
17. Kyle, U.G., Bosaeus, I., De Lorenzo, A.D., Deurenberg, P., Elia, M., Gómez, J.M., Lheitmann, B., Kent-Smith, L., Melchior, J.-C., Pirlich, M., Scharfetter, H., Schols, A.M.W.J. Pichard, C. 2004 Bioelectrical impedance analysis - Part II: Utilization in clinical practice. Clinical Nutrition, 23, 1430 1453.
18. Gómez, J.M., Espadero, R.M., Escobar-Jiménez, F., Hawkins, F., Picó, A., Herrera-Pombo, J.L., Vilardell, E., Durán, A., Mesa, J., Faure, E. Sanmartí, A. 2002 Growth hormone release after glucagon as a reliable test of growth hormone assessment in adults. Clinical Endocrinology, 56, 329 334.
19. Celermajer, D.S., Sorensen, K.E., Gooch, V.M., Spregelhalter, G.M., Miller, O.I., Sullivan, I.D., Loyd, J.K. Dranfield, J.E. 1992 Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet, 340, 1111 1115.
20. Matthews, D.R., Hosker, J.P., Rudenski, A.S., Naylor, B.A., Treacher, D.F. Turner, R.C. 1985 Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucosa and insulin concentrations in man. Diabetologia, 28, 412 419.
21. Rossner, B. 1995 Fundamentals of Biostatistics, 4th edn. Duxbury Press, New York.
22. Dever, G. 1980 Basic statistical measures for community health analysis. In : Community Health Analysis. A Holistic Approach. Aspen Systems Corporation, Rockville, MD 70 85.
23. Yuen, K.C.J., Frystyk, J., White, D.K., Twickler, ThB., Koppeschaar, H.P.F., Harris, P.E., Fryklund, L., Murgatroyd, P.R. Dunger, D.B. 2005 Improvement in insulin sensitivity without concomitant changes in body composition and cardiovascular risk markers following fixed administration of a very low growth hormone (GH) dose in adults with severe GH deficiency. Clinical Endocrinology, 63, 428 436.
24. Keleçtimur, F., Jonsson, P., Molvalilar, S., Gómez, J.M., Auernhammer, C., Colak, R., Koltowska-Häggström, M. Goth, M. 2005 Sheehan's syndrome: baseline characteristics and effect of two years of growth hormone replacement therapy in 91 patients in KIMS - Pfizer International Metabolic Database. European Journal of Endocrinology, 152, 581 587.
25. Wellen, E., Gökhan, S. Hotamisligil, S. 2005 Inflammation, stress, and diabetes. Journal of Clinical Investigation, 115, 1111 1119.
26. Ross, R. 1999 Atherosclerosis - an inflammatory disease. New England Journal of Medicine, 340, 115 126.
27. Linton, M. Fazio, S. 2003 Macrophages, inflammation, and atherosclerosis. International Journal of Obesity, 27, S35 S40.
28. Magyar, M.T., Sxiksazai, Z., Balla, J., Valikovics, A., Kappelmayer, J., Imre, S., Balla, G., Jeney, V., Csiba, L. Bereczki, D. 2003 Early-onset carotid atherosclerosis is associated with increased intima-media thickness and elevated serum levels of inflammatory markers. Stroke, 34, 58 66.
29. Elhadd, T.A., Abdu, T.A., Oxtoby, J., Kennedy, G., McLaren, M., Neary, R., Belch, J.J. Clayton, R.N. 2001 Biochemical and biophysical markers of endothelial dysfunction in adults with hypopituitarism and severe GH deficiency. Journal of Clinical Endocrinology and Metabolism, 86, 4223 4232.
30. Colao, A., Di Somma, C., Pivonello, R., Cuocolo, A., Spinelli, L., Bonaduce, D., Salvatore, M. Lombardi, G. 2002 The cardiovascular risk of adult GH deficiency (GHD) improved after GH replacement and worsened in untreated GHD: a 12-month prospective study. Journal of Clinical Endocrinology and Metabolism, 87, 1088 1093.
31. Abdu, T.A.M., Elhadd, T.A., Buch, H., Barton, D., Neary, R. Clayton, R.N. 2004 Recombinant GH replacement in hypopituitary adults improves endothelial cell function and reduces calculated absolute and relative coronary risk. Clinical Endocrinology, 61, 387 383.
32. Kvaniscka, J., Marek, J., Kvaniscka, T., Weiss, V., Markova, M., Stepan, P. Umlaufova, A. 2000 Increase of adhesion molecules, fibrinogen, plasminogen activator inhibitor and orosomucoid in growth hormone deficient adults and its modulation by recombinant human GH replacement. Clinical Endocrinology, 52, 543 548.
33. Böger, R.H., Skamira, C., Bode-Bóger, S.M., Brabant, G., von zur Mühlen, A. Frölich, J.C. 1996 Nitric oxide may mediate the hemodynamic effects of recombinant growth hormone in patients with acquired growth hormone deficiency. Journal of Clinical Investigation, 98, 2706 2713.
34. Bruunsgaard, H. Pedersen, B.K. 2003 Age-related inflammatory cytokines and disease. Immunology and Allergy Clinics of North America, 23, 15 39.
35. Ferrucci, L., Corsi, A., Lauretani, F., Bandinelli, S., Bartali, B., Taub, D.D., Guralnik, J.M. Longo, D.L. 2005 The origins of age-related proinflammatory state. Blood, 105, 2294 2299.
36. Sesmilo, G., Biller, B.M.K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N. Klibanski, A. 2000 Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone deficiency: a randomised, controlled clinical trial. Annals of Internal Medicine, 133, 111 122.
37. Danesh, J., Wheeler, J.G., Hirschfield, G.M., Eda, S., Eiriksdottir, G., Rumley, A., Lowe, G.D., Pepys, M.B. Gudnason, V. 2004 C-reactive protein and other circulating markers of inflammation in the prediction of coronary of heart disease. New England Journal of Medicine, 350, 1387 1397.
38. Irving, R.J., Carson, M.N., Webb, D.J. Walker, B.R. 2002 Peripheral vascular structure and function in men with contrasting GH levels. Journal of Clinical Endocrinology and Metabolism, 87, 3309 3314.
39. Fernández-Castañer, M., Camps, I., Fernández-Real, J.M., Domènech, P. Martínez-Brotons, F. 1996 Increased prothrombin fragment 1+2 and D-dimer in first-degree relatives of type 2 diabetic patients. Acta Diabetologica, 33, 118 121.
40. Calles-Scandon, J. Cipolla, M. 2001 Diabetes and endothelial dysfunction: a clinical perspective. Endocrine Reviews, 22, 36 52.
41. Hung, J., McQuillan, B., Chapman, C., Thompson, P. Beilby, J. 2005 Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arteriosclerosis, Thrombosis and Vascular Biology, 25, 1268 1273.
42. Fasshauer, M., Klein, J., Kralisch, S., Klier, K., Lossner, U., Bluher, M. Paschke, R. 2004 Monocyte chemoattractant protein 1 expression is stimulated by growth hormone and interleukine-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications, 317, 598 604.
43. Egashira, K. 2002 Molecular mechanisms mediating inflammation in vascular disease. Special reference to monocyte chemoattractant protein-1. Hypertension, 41, 834 841.
44. Dahman, I., Kaaman, M., Olsson, T., Tan, G., Wahlen, K., Anderson, J., Norström, E., Blomqvist, L., Sjörgren, A., Forsgren, M., Attersand, A. Arner, P. 2005 A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. Journal of Clinical Endocrinology and Metabolism, 90, 5834 5840.
45. Fasshauer, M., Klein, J., Kralish, S., Klier, M., Lossner, U., Bluher, M. Paschke, R. 2004 Monocyte chemoattractant protein 1 is stimulated by growth hormone and interleukin-6 in 3T3-L1 adipocytes. Biochemical and Biophysical Research Communications, 317, 598 604.
46. Evans, L.M., Davies, J.S., Anderson, R.A., Ellis, G.R., Jackson, S.K., Lewis, M.J., Frenneaus, M.P., Ress, A. Scanlon, M.F. 2000 The effect of GH replacement therapy on endothelial function and oxidative stress in adult growth hormone deficiency. European Journal of Endocrinology, 142, 254 262.
47. Smith, J.C., Evans, L.M., Wilkinson, I., Goodfellow, J., Cockctroft, J.R., Scanlon, M.F. Davies, J.S. 2002 Effects of GH replacement on endothelial function and large-artery stiffness in GH-deficient adults: a randomised, double-blind, placebo-controlled study. Clinical Endocrinology, 56, 493 501.
48. Hána, V., Prázný, M., Marek, J., Skraha, J. Justová, V. 2002 Reduced microvascular perfusion and reactivity in adult GH deficient patients is restored by GH replacement. European Journal of Endocrinology, 147, 333 337.
49. Mohn, A., Di Marzio, D., Giannini, C., Capanna, R., Marcovecchio, M. Chiarelli, F. 2005 Alterations in the oxidant-antioxidant status in prepubertal children with growth hormone deficiency: effect of growth hormone replacement therapy. Clinical Endocrinology, 63, 537 542.